Abstract
Purpose
To evaluate the visual outcomes of choroidal neovascularization (CNV) secondary to pathological myopia in eyes treated with photodynamic therapy (PDT), and to determine the effect of lesion location and foveal involvement on visual prognosis.
Methods
Interventional case series of 24 consecutive patients with myopic CNV treated with PDT. The main outcome measure was final LogMAR visual acuity (VA).
Results
Of 24 eyes, the CNV lesion was subfoveal in 11 and extrafoveal in 13. Overall, the mean LogMAR VA at 24 months was 0.72. Extrafoveal CNV lesions achieved significantly better final VA compared with subfoveal CNV (LogMAR 0.45 vs 1.05, P=0.012). Eyes with extrafoveal CNV lesions were subdivided into foveal-sparing PDT (where the PDT laser spot did not involve the foveal center) and foveal-involved PDT (where the PDT laser covered the fovea). At all time points, the group with foveal-sparing PDT had significantly better VA compared with the foveal-involved group. The final LogMAR VA for the foveal-sparing PDT group was 0.26 compared with 1.00 for the foveal-involved PDT group (P=0.003). At 24 months, 77.8% of foveal-sparing PDT cases achieved VA of ≥20/40, compared with 25% of foveal-involved PDT cases and 9.1% of subfoveal CNV lesions (P=0.006).
Conclusion
For patients with myopic CNV, foveal-sparing PDT results in significantly better long-term visual outcomes compared with those with foveal-involved PDT. Foveal-sparing PDT may be of value for treatment of myopic CNV patients who are not suitable for treatment with anti-vascular endothelial growth factor injections.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing eye study. Ophthalmology 2006; 113 (7): 1134.e1–1134.e11.
Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi study. Ophthalmology 2006; 113 (8): 1354–1362.
Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110 (7): 1297–1305.
Hampton GR, Kohen D, Bird AC . Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90 (8): 923–926.
Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology 2001; 108 (5): 841–852.
Hayashi K, Shimada N, Moriyama M, Hayashi W, Tokoro T, Ohno-Matsui K et al. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012; 32 (4): 687–695.
Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148 (3): 396–408.
Yoon J, Byun Y, Koh H . Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30 (3): 418–424.
Ruiz-Moreno J, Montero J, Amat-Peral P . Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011; 249 (4): 595–599.
Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011; 25 (3): 375–381.
Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147 (1): 94–100.
Lai T, Chan W, Liu D, Lam D . Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29 (6): 750–756.
Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011; 152 (2): 266–272.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119 (7): 1388–1398.
IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119 (7): 1399–1411.
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246 (1): 81–87.
Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145 (5): 879–882.
TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117 (10): 1329–1345.
Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara W et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008; 145 (3): 518–526.
Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Hayashi W, Wang J et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 2010; 151 (1): 137–147.
Coutinho AM, Silva RM, Nunes SG, Cachulo ML, Figueira JP, Murta JN et al. Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina 2011; 31 (6): 1089–1094.
Lam D, Chan W, Liu D, Fan D, Lai W, Chong K et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004; 88 (10): 1315–1319.
Lam D, Liu D, Fan D, Lai W, So S, Chan W et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye (Lond) 2005; 19 (8): 834–840.
Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149 (1): 140–146.
Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94 (7): 864–870.
Pece A, Vadalà M, Isola V, Matranga D . Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007; 143 (3): 449–454.
Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F . Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128 (4): 437–442.
Ruiz-Moreno J, Amat P, Montero J, Lugo F . Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92 (6): 792–794.
Giansanti F, Virgili G, Donati MC, Giuntoli M, Pieretti G, Abbruzzese G et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012; 32 (8): 1547–1552.
Axer-Siegel R, Ehrlich R, Weinberger D, Rosenblatt I, Shani L, Yassur Y et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004; 138 (4): 602–607.
Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012; 96 (8): 1068–1072.
Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2013; 251 (1): 1–7.
Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt K, Ziemssen F et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010; 248 (4): 543–550..
Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010; 30 (10): 1609–1615.
Vadalà M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 2011; 95 (5): 657–661.
Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ . Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Retina 2012; 32 (5): 949–955.
Acknowledgements
Dr Tan receives research support from the National Healthcare Group Clinician Scientist Career Scheme Grant CSCS/12005 and Clinician Leadership in Research Grant CLR-09006.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Tan receives travel support from Novartis and Bayer. Professor Lim receives travel support from Novartis, Bayer, and Heidelberg Engineering.
Rights and permissions
About this article
Cite this article
Tan, C., Chew, M. & Lim, T. Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye 28, 17–22 (2014). https://doi.org/10.1038/eye.2013.204
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2013.204
Keywords
This article is cited by
-
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
BMC Ophthalmology (2020)
-
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV
Graefe's Archive for Clinical and Experimental Ophthalmology (2016)
-
Letter to the editor: Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization
Graefe's Archive for Clinical and Experimental Ophthalmology (2016)
-
Response to the letter to the editor entitled "Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization"
Graefe's Archive for Clinical and Experimental Ophthalmology (2016)
-
Comparability of retinal thickness measurements using different scanning protocols on spectral-domain optical coherence tomography
International Ophthalmology (2016)
